Enterprise Access
Enterprise Access is for pharma, biotech, AI-health companies, clinic networks, research institutions, investors, acquirers, and strategic partners that need structured evaluation of the BioAtlas platform, data estate, route architecture, commercial packaging, and protected intelligence surfaces.
This tier treats BioAtlas as more than an application. It is a biomedical intelligence estate with software, datasets, APIs, engines, registries, dashboards, research assets, pharmacology layers, clinical workflows, and AI-assisted navigation that can be reviewed, licensed, deployed, partnered, or acquired under controlled terms.
generated application pages
API route files
API-backed intelligence routes
JSON data files
Enterprise Access positions BioAtlas as infrastructure: a large biomedical intelligence estate spanning routes, APIs, datasets, registries, engines, fieldmaps, clinical dashboards, research surfaces, pharmacology layers, and AI-guided navigation.
Enterprise users can evaluate target context, drug-class logic, repurposing intelligence, oncology pathways, PCD layers, natural systems pharmacology, mechanism mapping, and disease-state interpretation inside reviewed commercial and diligence environments.
BioAtlas can act as a structured biomedical reasoning layer for AI-health companies that need target-aware, mechanism-aware, system-aware, and clinically bounded biological context without collapsing access rights into unrestricted model training.
Enterprise Access can support white-label portals, selected verticals, custom domains, controlled dataset/API access, reporting layers, education layers, usage analytics, support retainers, and strategic partnership structures.
Enterprise estate scale
generated application pages
API route files
API-backed intelligence routes
JSON data files
modular dataset, registry, and catalogue files
likely engine, module, or controller files
clean pharmaceutical / drug-target rows
synergy-related audit hits
Target intelligence, drug-class context, oncology logic, pathway reasoning, repurposing review, mechanism interpretation, and disease-state mapping.
Structured biomedical reasoning, API evaluation, retrieval licensing, embedding separation, clinical boundary enforcement, and protected training-rights negotiation.
Clinical dashboards, biomarker interpretation, safe formulation support, practitioner education, report generation, vault workflows, and multi-site continuity.
Natural systems pharmacology, ingredient selection, compound synergy, ECS optimisation, product-category logic, and white-label formulation intelligence.
Gut-brain-ECS axis, SCFA logic, microbial metabolite maps, immune-gut signalling, barrier function, and microbiome-compound links.
Platform review, diligence packaging, asset mapping, commercial rights, route architecture, data boundaries, and acquisition-readiness evaluation.
Enterprise conversations should be scoped carefully. API access, dataset licensing, embedding rights, AI training rights, clinical deployment, white-label use, sector exclusivity, and acquisition discussions are separate commercial lanes.
Request enterprise reviewReviewed registration
Submit this form from the route that best matches your intended use. Requests are reviewed before protected clinical, research, commercial, dataset, API, protected intelligence, or diligence access is opened.